The FDA Pulled the Plug on Your Peptide Stack — And the Gray Market Exploded Anyway

The FDA Pulled the Plug on Your Peptide Stack — And the Gray Market Exploded Anyway

The "regulatory gray zone" that biohackers relied on for compounds like BPC-157 and TB-500 closed in September 2023. That's when the FDA placed both peptides into Category 2 — officially classified as "do not compound" — citing concerns about immunogenicity, peptide-related impurities, and a critical absence of human safety data. In December 2024, the FDA's Pharmacy Compounding Advisory Committee voted against allowing compounding of ipamorelin, MK-677, CJC-1295, and AOD-9604 as well. FDA documentation from that review specifically flagged adverse findings in nonclinical studies for CJC-1295, including DNA damage in pituitary cells. The gray zone framing, according to one longevity physician who wrote a detailed breakdown, "has not been accurate since September 2023, and in 2026 it is significantly misleading."

What's happened since is a study in how regulation and demand diverge. Legitimate compounding pharmacies are out. But the compounds are still moving — sourced increasingly from unregulated channels where purity, sterility, and actual peptide identity are unverified. The FDA's concern isn't abstract: the gap between animal findings and human outcomes is where most drugs go to die, and the evidence base for many of these injectable peptides leans heavily on preclinical data, often from limited or non-independent sources.

The information asymmetry is the real danger here. Most users are making injection decisions based on a research landscape they haven't examined and a regulatory status that shifted over two years ago.

Gobble's Take: Injecting something the FDA flagged for DNA damage in pituitary cells is not biohacking — it's just skipping the part where you read the warning label.

Source: Your Next Door PCP

Jeff Bezos Put $3 Billion on a Single Question: Can You Rewind a Human Cell?

Jeff Bezos committed $3 billion to Altos Labs. Sam Altman wrote a personal check for $180 million to Retro Biosciences, then backed a $1 billion Series A. Peter Thiel funded the Methuselah Foundation. None of these are philanthropic gestures — they are calculated bets on the premise that aging is a process that can be interrupted, and that the companies proving it first will be worth more than anything being built today. One analysis frames it directly: "The same way semiconductors became the substrate of the digital economy, DNA is becoming the substrate of the biological one."

The science behind the bets traces back to 2006, when Japanese researcher Shinya Yamanaka discovered four specific genes — now called the Yamanaka factors — that could reprogram mature, aged cells back toward an embryonic-like state. He won the Nobel Prize. In petri dishes, skin cells from 90-year-olds have been returned to a younger state. In mice, gray hair has turned black and muscle strength has returned. The race now is whether this can be done safely in a living human body at scale, without triggering tumor growth — a question the entire field is organized around answering.

Altos Labs, the largest biotech startup launch in history, now has labs in the Bay Area, San Diego, Cambridge UK, and Japan. Its scientists are currently testing reprogramming therapies in human organs removed from the body and kept alive on perfusion machines — gathering human-adjacent data without whole-body trial risk. Retro Biosciences, working with OpenAI, used AI to redesign the Yamanaka factors and reported a 50-fold increase in reprogramming efficiency. Retro Biosciences is now in early human trials in Australia with RTR242, a pill designed to reverse Alzheimer's by restoring cellular recycling.

Gobble's Take: When the world's wealthiest people stop buying yachts and start buying cellular reprogramming labs, it's worth asking what they know about aging that you don't.

Source: Genomics Media

The Scientist Who Helped Discover Rapamycin's Power Takes Just Three Supplements

Dr. Brian Kennedy's 85-year-old mother started on a treadmill. Now she does pec flies. He brings this up not as a side note, but as the point — because after co-authoring one of the first papers showing that decreased TOR signaling extends chronological lifespan in yeast, after leading the Buck Institute for Research on Aging, and after relocating to Singapore eight years ago to sit at the center of one of the world's most deliberate healthspan experiments, Kennedy's philosophy has landed somewhere unexpected: less is more, and exercise is irreplaceable.

His own supplement stack is three items. He takes a time-release form of alpha-ketoglutarate, a natural metabolite that declines with age. For NAD — a cofactor critical to cellular energy and repair that also falls with age — he uses a sublingual form for direct absorption, and reports a noticeable effect on his running performance. His third addition is astaxanthin, a potent antioxidant, which he's currently testing personally. The restraint is deliberate. Kennedy has seen in animal models that combining supplements can produce canceling effects or cause harm — what sounds like synergy on paper doesn't always behave that way in a living system.

His caution is grounded in the same scientific rigor that led him to call rapamycin "still the gold standard for a drug that is likely to slow ageing." Singapore, where he chose to base his work, is the backdrop for why this matters: by 2030, roughly one in four residents will be 65 or older, and the old-age support ratio is projected to fall to just over two working-age adults per senior. In that environment, the question isn't just how long people live — it's how long they stay functional.

Gobble's Take: A man who helped prove rapamycin slows aging in yeast takes three supplements and his best longevity intervention is getting his mother to lift weights — maybe the stack you need is shorter than you think.

Source: Seoul to Soul

Your Blood Contains a Peptide That Resets 4,000 Genes — and It Tanks by 60% After 40

In 1973, researchers at UCSF discovered something strange: when they exposed older liver tissue to blood plasma from young adults aged 20 to 25, the older tissue began producing proteins that looked like it came from a younger body. The active molecule behind that effect was GHK — a tripeptide made of three amino acids that your body produces naturally and releases into your bloodstream. Your GHK levels peak around age 20 at roughly 200 ng/mL. By age 60, they've dropped to about 80 ng/mL. That 60% decline tracks closely with many of the cellular changes associated with biological aging.

When researchers later used genomic tools from the Broad Institute — a joint Harvard/MIT research organization — to look at GHK's effect on the entire human genome at once rather than one gene at a time, the findings were striking. GHK significantly alters the activity of roughly 31% of all human genes, approximately 4,000 genes. The direction of those changes is consistent: genes associated with inflammation, tissue destruction, and cellular aging quiet down; genes linked to healing, antioxidant defense, and cellular repair become more active. Most drugs target a single pathway. GHK appears to shift the whole system.

When combined with copper ions, forming the complex GHK-Cu, this same molecule has been studied for decades across wound healing, collagen synthesis, anti-inflammatory signaling, and more — though much of the research, it's worth noting, is still building toward robust human clinical evidence. A recent video discussing GHK-Cu was flagged by Meta as "drug-related" and removed — an algorithmic decision that, whatever its intent, managed to treat a naturally occurring human peptide the same way it would treat illicit drug promotion.

Gobble's Take: A molecule your own body makes, that your body stops making as you age, was censored by an algorithm — the most telling sign yet that the conversation about longevity biology is years ahead of the infrastructure meant to govern it.

Source: Dr. Kristi Sawicki

Your Brain Makes Its Own Antioxidant — But Only If You Give It the Right Light

Your brain accounts for 2% of your body weight and burns through 20% of your body's energy. That metabolic load comes with a cost: it produces oxidative byproducts constantly, and it becomes increasingly bad at cleaning them up with age. A newly published paper in the journal Cureus argues there's a largely overlooked defense mechanism that can help — one triggered not by a supplement, but by near-infrared light absorbed directly by mitochondria inside your neurons.

The mechanism works like this: near-infrared (NIR) light, a component of natural sunlight invisible to the eye, penetrates tissue and is absorbed by mitochondria. That absorption triggers localized melatonin production — not the melatonin that signals sleep, but a mitochondria-specific antioxidant response that quenches oxidative damage at the site where it's generated. The paper describes two coordinated defense systems that activate: one reduces damaging oxygen byproducts inside the mitochondria, the other protects cell membranes from toxic breakdown products that can spread cellular damage. The key qualifier is dosing: the research describes a "Goldilocks principle" where moderate exposure may produce benefits, but too little or too much yields no effect or potential harm, particularly in sensitive brain tissue.

The most direct application discussed is Alzheimer's disease, where some studies show patients have early mitochondrial dysfunction and reduced melatonin levels. Human trials, however, remain limited and inconclusive — the paper is a mechanistic and theoretical framework, not a clinical endorsement. What it does establish is a plausible biological pathway connecting light exposure, mitochondrial health, and brain resilience that warrants serious investigation.

Gobble's Take: Your mitochondria have a built-in antioxidant factory and all it needs is sunlight — the fact that most people spend their days under fluorescent lights is less a lifestyle choice and more a slow deprivation experiment.

Source: Take Control

In Case You Missed It

Yesterday's top stories:

• Your DNA Sets the Clock. Science Is Learning to Wind It Back.
• The 12-Step Biological Checklist That's Turning Anti-Aging Into a Science
• Your Supplement Stack Is Probably a Wallet Biopsy
• From 73 Beers to Red-Light Therapy: Pro Athletes Are Becoming Longevity Labs With Jerseys